Ceftriaxone use for community bloodstream infections is associated with tripled thirty-day mortality

A systematic review and meta-analysis of eleven studies (n=2,568) found that ceftriaxone use for methicillin-sensitive Staphylococcus aureus bloodstream infections (MSSA-BSI) was associated with a three-fold increase in 30-day mortality compared with standard of care — anti-staphylococcal penicillins or cefazolin (OR 3.33, 95% CI 2.17–5.10; Maraolo et al., Annals of Medicine, 2026; PMID 42112603). The difference at 90 days was not statistically significant (OR 1.71, 95% CI 0.75–3.90); the short-term mortality signal was consistent across the included studies.

Ceftriaxone is the most widely used agent in community IV antibiotic services owing to its once-daily dosing and stability profile — a rational operational choice where more complex administration schedules are impractical. The mortality signal does not challenge outpatient parenteral antibiotic therapy as a model of care. It identifies a specific antimicrobial selection problem: when empiric ceftriaxone is applied before pathogen confirmation, or when logistical convenience is treated as a clinical rationale, the risk is material and measurable.

The finding is consistent with an Italian scoping review (23 studies, 2000–2025) confirming ceftriaxone as the most common agent in OPAT services alongside persistent implementation fragmentation across programmes (PMID 41661512). Community antimicrobial services operating on empiric ceftriaxone protocols for undifferentiated bacteraemia should treat this signal as a governance prompt: audit pathogen-directed escalation criteria and confirm that de-escalation to anti-staphylococcal agents occurs consistently on Gram-positive bloodstream results.

World best practice in antimicrobial stewardship — including international OPAT guidelines — places pathogen-directed therapy as non-negotiable. The gap between operational convenience and clinical safety in community IV services is now quantified.